Issue Date: July 24, 2006
... and diabetes drug from Ipsen
Roche will license, develop, and market Ipsen's antidiabetes drug BIM 51077, a glucagon-like peptide 1 (GLP-1) analog. Roche decided to exercise its option under a 2003 agreement following favorable Phase I and II clinical trials. Roche will pay Ipsen $71 million up front and an additional $3.8 million after closing of Ipsen's 2006 financial statements. Additional milestone payments to Ipsen could total $214 million.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society